TY - JOUR
T1 - COVID-19
T2 - Pharmacology and kinetics of viral clearance
AU - Farina, Nicola
AU - Ramirez, Giuseppe A.
AU - De Lorenzo, Rebecca
AU - Di Filippo, Luigi
AU - Conte, Caterina
AU - Ciceri, Fabio
AU - Manfredi, Angelo A.
AU - Rovere-Querini, Patrizia
N1 - Funding Information:
This work of the authors has been supported by a COVID-19 program project grant from the IRCCS San Raffaele Hospital and by the grant COVID-2020-12371617 from the Italian Ministry of Health .
Publisher Copyright:
© 2020 Elsevier Ltd
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/11
Y1 - 2020/11
N2 - Coronavirus Disease 2019 (COVID-19) is a pandemic disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical spectrum of COVID-19 is broad and varies from mild to severe forms complicated by acute respiratory distress and death. This heterogeneity might reflect the ability of the host immune system to interact with SARS-CoV2 or the characteristics of the virus itself in terms of loads or persistence. Information on this issue might derive from interventional studies. However, results from high-quality trials are scarce. Here we evaluate the level of evidence of available published interventional studies, with a focus on randomised controlled trials and the efficacy of therapies on clinical outcomes. Moreover, we present data on a large cohort of well-characterized patients hospitalized at a single University Hospital in Milano (Italy), correlating viral clearance with clinical and biochemical features of patients.
AB - Coronavirus Disease 2019 (COVID-19) is a pandemic disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical spectrum of COVID-19 is broad and varies from mild to severe forms complicated by acute respiratory distress and death. This heterogeneity might reflect the ability of the host immune system to interact with SARS-CoV2 or the characteristics of the virus itself in terms of loads or persistence. Information on this issue might derive from interventional studies. However, results from high-quality trials are scarce. Here we evaluate the level of evidence of available published interventional studies, with a focus on randomised controlled trials and the efficacy of therapies on clinical outcomes. Moreover, we present data on a large cohort of well-characterized patients hospitalized at a single University Hospital in Milano (Italy), correlating viral clearance with clinical and biochemical features of patients.
KW - COVID-19
KW - Pharmacology
KW - SARS-CoV-2
KW - Viral clearance kinetics
UR - http://www.scopus.com/inward/record.url?scp=85089411949&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089411949&partnerID=8YFLogxK
U2 - 10.1016/j.phrs.2020.105114
DO - 10.1016/j.phrs.2020.105114
M3 - Review article
C2 - 32758635
AN - SCOPUS:85089411949
VL - 161
JO - Pharmacological Research
JF - Pharmacological Research
SN - 1043-6618
M1 - 105114
ER -